First AD

Second AD

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD

OncLive News Network®

Cedars-Sinai Cancer

Cancer Centers

Partner

USC Norris Comprehensive Cancer Center

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape. 

Future Directions in Chronic GvHD

The Chronic GvHD Landscape:  Risk Factors and Diagnosis 

First-line Treatment for Patients with Chronic GvHD

Defining and Managing Steroid Refractory Chronic GvHD

Role of Ruxolitinib in Steroid-Refractory Chronic GvHD

Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil

Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients

Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD